Guangming welcomes 3 biomedicine giants

Guangming District revealed plans for a specialized industrial zone dedicated to the biomedicine sector during the Shenzhen Biomedicine Industry Investment Promotion Conference on Sept. 10.

This initiative is expected to foster a comprehensive ecosystem that encompasses original innovation, research and development, manufacturing, and application within the biomedicine field.

During the project signing session, Guangming District secured partnerships with three significant companies: Shinva Medical Instrument Co. Ltd., Shanghai MicroPort Medbot (Group) Co. Ltd., and Bloomage Biotech.

Shinva Medical Instrument Co. Ltd.

Established in 1943, Shinva Medical Instrument Co. Ltd. has grown to become a pivotal player in the health industry in China. Listed on the Shanghai Stock Exchange in September 2002, Shinva has integrated various facets of the medical and pharmaceutical fields, including scientific research, production, sales, medical services, and trade logistics. This multifaceted approach has enabled the company to achieve significant milestones and continuously contribute to improving healthcare quality both domestically and internationally.

Shinva Medical announced plans to establish its GBA Innovation Headquarters in Guangming, along with a high-end medical equipment innovation center and dental equipment projects. The company aims to form a high-end medical equipment industry innovation alliance.

Shanghai MicroPort MedBot (Group) Co. Ltd.

The company has emerged as a trailblazer in the field of robotic surgery since its inception. The development of MedBot began in 2014 as an internal incubation project within the MicroPort group, culminating in the establishment of a dedicated company in 2015. With a focus on meeting the growing demand for advanced surgical technology, MedBot is at the forefront of innovation, particularly with its flagship product, the SkyWalker orthopedic surgical robot.

MedBot revealed their intentions to create a GBA center in the district, which will encompass a comprehensive innovation base featuring a surgical robot research institute and various core components for surgical and aesthetic robots. This initiative aims to bolster Guangming Science City's role as an international biomedicine innovation center while launching MicroPort's second global R&D center for surgical robots.

Bloomage Biotech

Bloomage Biotech began its journey in 2000 as a producer of hyaluronic acid through microbial fermentation. Over the past two decades, the company has established itself as a global leader in biotechnology and biomaterials, specializing in the industrialization of hyaluronic acid. Bloomage has redefined the production processes for hyaluronic acid, offering over 200 product specifications for pharmaceutical, cosmetic, and food-grade applications. 

Bloomage plans to capitalize on Guangming District's policy and resource advantages by establishing its southern headquarters. The objective is to enhance the integration and development of the biomanufacturing industry's supply chain.

The commitment of these industry leaders marks a pivotal step in positioning Guangming District as a leader in biomedicine and advanced medical technology.